Patients with primary central nervous system lymphoma had high response rates and good long-term disease control with a chemotherapy regimen followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in a new phase II trial.
The combination of palifosfamide and doxorubicin was no better than doxorubicin and placebo in the phase III PICASSO 3 trial of patients with metastatic soft-tissue sarcoma.
A new study shows that additional RAS mutations can confer resistance to panitumumab, an epidermal growth factor receptor (EGFR) antibody approved for treating metastatic colorectal cancer.
Men aged 75 and older generally do not benefit from annual PSA screening, but a new study shows that Medicare spending on PSA screening for this population continues.
A combination regimen of erlotinib and the selective MET inhibitor tivantinib did not improve overall survival compared with erlotinib and placebo among patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer.
A novel agent that inhibits the PD-1/PD-L1 pathway showed good results in particular among smokers with non-small-cell lung cancer, a particularly promising result from a phase I trial.
A phase III study of the therapeutic lung cancer vaccine belagenpumatucel-L (Lucanix) failed to meet its predefined endpoint, but the vaccine showed a “considerable” increase in overall survival in patients with non–small-cell lung cancer.
The results of a phase III randomized trial found that the anti-angiogenesis antibody ramucirumab improved survival in advanced, previously treated gastric cancer.
The mTOR inhibitor everolimus showed clinical efficacy for the initial treatment of advanced papillary renal cell carcinoma, according to the phase II results of the RAPTOR trial.
Postoperative irradiation of the internal mammary and medial supraclavicular lymph nodes of patients with early breast cancer resulted in improved survival with no increase in side effects, according to 10-year follow-up results.